Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar;84(3):418-467.
doi: 10.1016/j.jinf.2021.11.013. Epub 2021 Nov 20.

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis

Lili Luo  1 , Ting Luo  2 , Mengyi Du  1 , Heng Mei  3 , Yu Hu  4
Affiliations
Meta-Analysis

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis

Lili Luo et al. J Infect. 2022 Mar.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Forest plot for the efficacy and safety of tocilizumab in randomized controlled trials. (A) 28–30 days mortality. (B) overall mortality. (C) Progression to mechanical ventilation. (D) Secondary infection. (E) Severe adverse events.
Fig. 1
Fig. 1
Forest plot for the efficacy and safety of tocilizumab in randomized controlled trials. (A) 28–30 days mortality. (B) overall mortality. (C) Progression to mechanical ventilation. (D) Secondary infection. (E) Severe adverse events.
Fig. 2
Fig. 2
Forest plot for the efficacy and safety of tocilizumab in cohort studies. (A) 28–30 days mortality. (B) overall mortality. (C) progression to mechanical ventilation. (D) secondary infection.
Fig. 2
Fig. 2
Forest plot for the efficacy and safety of tocilizumab in cohort studies. (A) 28–30 days mortality. (B) overall mortality. (C) progression to mechanical ventilation. (D) secondary infection.
See this image and copyright information in PMC

Comment in

References

    1. Coomes E.A., Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1–9. NovPubMed PMID: 32845568. Pubmed Central PMCID: PMC7460877. Epub 2020/08/28. eng. - PMC - PubMed
    1. Lan S.H., Lai C.C., Huang H.T., Chang S.P., Lu L.C., Hsueh P.R. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3) SepPubMed PMID: 32712333. Pubmed Central PMCID: PMC7377685. Epub 2020/07/28. eng. - PMC - PubMed
    1. Tharmarajah E., Buazon A., Patel V., Hannah J., Adas M., Allen V., et al. IL-6 inhibition in the treatment of COVID-19: a meta-analysis and meta-regression. J Infect. 2021 PubMed PMID: 33745918. - PMC - PubMed
    1. Chen C.X., Hu F., Wei J., Yuan L.T., Wen T.M., Gale R.P., et al. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) Leukemia. 2021;35(6):1661–1670. JunPubMed PMID: 34002026. Pubmed Central PMCID: PMC8127467 Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals. Advisor: Antegene Biotech LLC, Medical Director: FFF Enterprises Inc. Partner: AZACA Inc. Board of Directors: RakFond Foundation for Cancer Research Support. Scientific Advisory Board, StemRad Ltd. All other authors declare no competing interests. Epub 2021/05/19. eng. - PMC - PubMed
    1. Group R.C. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. PubMed PMID: 33933206. - PMC - PubMed

Substances